Make sure your doctor knows if you are pregnant or breastfeeding, or if you have a history of asthma, stomach ulcers or bleeding, liver disease, kidney disease, or if you have ever had breathing problems after taking aspirin or another type of nsaid. We use cookies for a number of reasons, such as keeping ft sites reliable and secure, personalising content and ads, providing social media features and. Skyepharma plc clarification of financial position biospace. If this is an annual report, indicate by check mark whether the registrant is a shell company. Summary live market news shares comment trades director deals broker forecasts fundamentals historic prices. Skp, the expert oral and inhalation drug development company, announces that its oral business has signed an exclusive feasibility, development and licence agreement with lucideon limited, part of lucideon group ltd lucideon, the international materials development and commercialisation. Investing in biotechnology stocks by leo gough, hardcover. Skyepharma then acquires jago ag, operating under that. Skp skyepharma is a drug research and development company with a leading drug deliveries technology business, specialising in. We provide tailormade solutions to our customers by positioning ourselves as an integrated partner offering a wide range of premium services. Is skyepharma plc a better buy than shire plc or hikma pharmaceuticals plc. You have to know whats happening with clients, competitors, practice areas, and industries.
The transition date to ifrs for skyepharma plc is january 1, 2004. The company operates as an independent developer of complex pharmaceutical products for global markets. With breakeven in sight, the company yesterday surprised the. It is based in chippenham and is listed on the london stock exchange. Whatever their position, each employee contributes to the development of the site. Skyepharma plc clarification of financial position read this article along with other careers information, tips and advice on biospace. Skyepharma plc announces regulatory application rns market newslondonmarketwire march 23, 2009 skyepharma announces filing of new drug applicationfor flutiformtm to the fda london, uk, 23. The name change reflects paciras transformation from a former business unit of skyepharma plc to an independent, private company with existing commercial products, a strong product in clinical development, and novel drug delivery. Skyepharma signs exclusive licensing agreement to access lucideons abuse deterrent drug delivery technology. Skyepharma has not attributed a value to these shares and they have been recorded at zero cost. Skyepharma strives to deliver a clinical benefit for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Founded in 1993 by brothers tom and david gardner, the motley fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and.
Skyepharma controlled release expertise is the result of years as a leader in drug development and oral drug delivery technologies serving the global pharmaceutical industry. In 2007 it acquired innovata plc, another developer of pulmonary products, and then moved on the full list of the london stock exchange. Food and drug administration fda in 2004 for use as a postsurgical pain reliever. Latest company news for skyepharma stock market wire. Skyepharma plc annual and transition report foreign private issuer 20f. In the legal profession, information is the key to success. Skyepharma is part of the vectura group of companies lse. Depodur cii, previously known as depomorphine, is a morphine sulfate extendedrelease liposome injection see depot injection, product of pacira pharmaceuticals formerly skyepharma plc. Vec, an industryleading device and formulation company specialized in airways disease. Skyepharma said its overall trading performance to endapril has been good and that directors continue to expect strong growth in revenues for fy 2016 compared with fy 2015. Skyepharmas audit committee has invited tenders from certain qualified auditing firms and the company will make a further announcement in due course when a new auditor has been.
Skyepharma acquires novel inhaled therapy platform. Uk key executives, insider trading, ownership, revenue and average growth rates. In 1999 it acquired coordinated drug development and the centre for drug formulation studies. Click the button below to request a report when hardcopies become available. Skyepharma plc does not currently have any hardcopy reports on. In 2004 it was listed on the alternative investment market. Skyepharma plc skyepharma or the company and vectura group plc vectura publication of scheme document on 16 march 2016, the boards of skyepharma and vectura announced that they had reached agreement regarding the terms of a recommended merger the merger. Skyepharma is teetering on the brink of joining one of the most exclusive clubs in town drugs research companies which make profits. The share data supplied on this page is provided by aj bell media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock screeners and investor research tools. Pharma job opportunities at skyepharma discover our cdmo. Working at skyepharma means being part of a team that is united, aligned and committed to the development of our facility.
Both companies make treatments for asthma and other. Skyepharma strives to deliver clinical benefits for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical. Skyepharma plc 4648 grosvenor gardens london, greater london sw1 w0eb phone. Its principal activities are the generation and development of product and drug delivery technology concepts. At december 31, 2005, the net book value of the tangible assets pledged as. Helping you bring inhaled medicines to market vectura. Through many years of involvement and achievements in the pharmaceutical industry, skyepharma s development and manufacturing facility is a leader in the field of classic and complex oral solid dosage forms.
Our value proposal includes tailored services to clients requirements supporting them up to market introduction. Prnewswire announces that a new market research report is available in its catalogue. View ken cunninghams profile on linkedin, the worlds largest professional community. Skyepharma plc annual and transition report foreign. Skyepharma ltd, formerly skyepharma plc, is a drug delivery company engaged in the development of oral and inhalation products. Skyepharma is a cdmo with expertise in classic and complex oral solid dosage forms. Skp dividends per share explanation, calculation, historical data and more. Director deals skyepharma plc skp peter grant, chief executive officer, bought 32 shares in the company on the 29th april 2016 at a price of 473. Skyepharma plc skyepharmasmission is to become one of the worlds leading speciality drug delivery companies, powered through excellence in its oral and inhalation technologies. Skyepharma plc has announced its plans to acquire depotech corp. Technologies and global markets, provides a detailed overview and detailed analysis of. On 10 june 2016 vectura completed a merger with skyepharma. Vectura group services limited free company information from companies house including registered office address, filing history, accounts, annual return, officers, charges, business activity. This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in skyepharma plc the company nor shall it form the basis of or be relied on in.
Vectura will present some of its most recent science in five poster presentations at the virtual respiratory drug delivery rdd. Free forex prices, toplists, indices and lots more. Sph stock quote sinclair pharma plc bloomberg markets. Vectura presents latest science at digital rdd 2020. Skyepharma fully integrated cdmo pharmaceutical oral solid. We strive to attract the best talents and to support them in their integration and development throughout their careers. The share data supplied on this page is provided by aj bell media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock. Ken cunningham chief executive officer skyepharma plc.
The shares were originally acquired consequent upon the acquisition of the assets of hyal pharmaceutical corp. This bcc research market research report, pulmonary drug delivery systems. Ian gowriesmith, founder of medeva, creates skyepharma plc as a virtual entity. Shares provides unbiased commentary, ideas, views and news on stocks, funds, pensions and savings. Skyepharma is a speciality drug delivery company with a proven range of oral and inhalation technologies. View profile view profile badges view similar profiles. Stock analysis for sinclair pharma plc sph including stock price, stock chart, company news, key statistics, fundamentals and company profile. Skyepharma share price history historical data for skp. Since it was founded, skyepharma has had a strong focus on oral drug delivery, solving the many challenges of delivering the right dose of a drug to the right part of the gastrointestinal system for absorption at the right time and at the appropriate rate to achieve the desired therapeutic effect. Investegate skyepharma plc announcements skyepharma plc. The motley fool uk has recommended hikma pharmaceuticals. The company was formed in 1997 as a startup pharmaceuticals business.
699 190 652 1101 675 208 226 263 433 1561 106 431 47 851 81 1488 940 1585 379 1082 1146 109 66 37 1457 751 920 1315 1224 971 1113 710 1060